venBio Partners LLC
In its 13F for Q3 2024 (holdings as of September 30, 2024, filed November 14, 2024), venBio Partners LLC reported 6 stock positions worth $194.3 million. Its top holding was Pharvaris (PHVS) at 40.9% of the portfolio, followed by Alumis (ALMS, 15.5%) and Harmony Biosciences (HRMY, 12.7%). Compared with Q2 2024, it opened 1 new position, sold out of 1 and reduced 1. The biggest buy was a new position in Artiva Biotherapeutics (ARTV) and the biggest sale an exit from Elevation Oncology (ELEV).
- Most Recent 13F
- Q2 2026
- Location
- SAN FRANCISCO, CA
- CIK
- 0001776382
- Portfolio Value
- $194.3M (Q3 2024)
- SEC Filing
- 0000905148-24-003147 ↗ filed Nov 14, 2024
Holdings Value
Holdings 6 stocks · $194.3M
| PHVS Pharvaris NV | 40.88% | 4,289,304 | $79.4M | No change |
| ALMS Alumis Inc. | 15.53% | 2,826,048 | $30.2M | No change |
| HRMY Harmony Biosciences Holdings | 12.65% | 614,594 | $24.6M | Reduce -40.6% |
| ARTV Artiva Biotherapeutics Inc. | 12.08% | 1,519,971 | $23.5M | New |
| SLRN Acelyrin Inc. | 9.77% | 3,852,470 | $19.0M | No change |
| ALXO Alx Oncology Holdings Inc. | 9.08% | 9,699,925 | $17.7M | No change |
Portfolio Sells Q2 2024 → Q3 2024
Portfolio Buys Q2 2024 → Q3 2024
| ARTV Artiva Biotherapeutics Inc. | New | 12.08% | +12.08 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 7 | $519.4M | PHVS, PBLS, ALMS, ACHV, ALXO |
| Q1 2026 | 6 | $280.6M | PHVS, ALMS, ALXO, HRMY, LYEL |
| Q4 2025 | 6 | $216.3M | PHVS, ALMS, HRMY, ALXO, LYEL |
| Q3 2025 | 6 | $176.4M | PHVS, ALMS, ALXO, HRMY, LYEL |
| Q2 2025 | 6 | $114.8M | PHVS, HRMY, ALMS, LYEL, ALXO |
| Q1 2025 | 7 | $123.6M | PHVS, ALMS, HRMY, SLRN, ALXO |
| Q4 2024 | 7 | $170.7M | PHVS, ALMS, HRMY, ALXO, ARTV |
| Q3 2024 | 6 | $194.3M | PHVS, ALMS, HRMY, ARTV, SLRN |
| Q2 2024 | 6 | $231.5M | PHVS, ALXO, ALMS, HRMY, SLRN |
| Q1 2024 | 5 | $281.9M | ALXO, PHVS, HRMY, SLRN, ELEV |